Akan, HamdiAydin, Seniz OngorenSaltoglu, NeseCagatay, AtahanAkalin, HalisArat, MutluAli, Ridvan2024-06-122024-06-1220141300-77771308-5263https://doi.org/10.4274/tjh.2014.0103https://hdl.handle.net/20.500.14551/21870The introduction of novel antifungal agents for the treatment of invasive fungal disease in hematological malignancies and also changing treatment strategies have had a great impact in managing affected patients. The medical literature includes some important clinical studies that are being used as evidence for guidelines. The problem with these studies and the guidelines is that they are not very easy to interpret, they include controversial issues, and they are not easy to apply to every patient or country. This paper was designed to critically show the main problems associated with these approaches and provide important information that will help Turkish doctors to adopt them in daily clinical practice.en10.4274/tjh.2014.0103info:eu-repo/semantics/openAccessInvasive Fungal InfectionAntifungal TreatmentEvidenceHematological MalignanciesLiposomal Amphotericin-BPreemptive Antifungal TherapyNeutropenic PatientsEmpirical-TreatmentPersistent FeverHigh-RiskFebrileAmbisomeVoriconazoleEfficacyArticle312111120Q4WOS:0003380946000012-s2.0-8490591211525035667Q3